Francesca Barone Sells 13,534 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Francesca Barone sold 13,534 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total value of $97,715.48. Following the completion of the transaction, the insider now directly owns 110,673 shares of the company’s stock, valued at approximately $799,059.06. This trade represents a 10.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Francesca Barone also recently made the following trade(s):

• On Wednesday, January 8th, Francesca Barone sold 13,673 shares of Candel Therapeutics stock. The shares were sold at an average price of $8.22, for a total value of $112,392.06.

Candel Therapeutics Stock Down 13.4 %

Shares of CADL stock opened at $6.66 on Friday. The stock has a market cap of $216.32 million, a PE ratio of -3.85 and a beta of -1.20. The business has a 50-day simple moving average of $6.61 and a 200-day simple moving average of $6.28. Candel Therapeutics, Inc. has a 52-week low of $1.16 and a 52-week high of $14.60.

Hedge Funds Weigh In On Candel Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Point72 DIFC Ltd purchased a new position in shares of Candel Therapeutics in the 2nd quarter valued at about $31,000. FMR LLC purchased a new position in shares of Candel Therapeutics in the 3rd quarter valued at about $46,000. MetLife Investment Management LLC purchased a new position in shares of Candel Therapeutics in the 3rd quarter valued at about $87,000. Atom Investors LP purchased a new position in shares of Candel Therapeutics in the 3rd quarter valued at about $103,000. Finally, Rhumbline Advisers purchased a new position in shares of Candel Therapeutics in the 2nd quarter valued at about $143,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $19.00 price objective (up previously from $11.00) on shares of Candel Therapeutics in a report on Wednesday, December 18th.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.